Fatal stimulation of acute myeloid leukemia blasts by pegfilgrastim

Area of Science:

• Hematology
• Pharmacology
• Oncology

Background:

• Acute myeloid leukemia (AML) treatment often involves myelosuppressive chemotherapy.
• Granulocyte colony-stimulating factors (G-CSFs) like pegfilgrastim are used to mitigate chemotherapy-induced neutropenia.
• Understanding G-CSF pharmacokinetics is crucial for optimizing AML patient management.

Observation:

• A male AML patient experienced unexplained, rapid blast proliferation post-chemotherapy.
• This hyperproliferation was investigated and linked to pegfilgrastim administration.
• The prolonged duration of pegfilgrastim's effects was identified as a key factor.

Findings:

• Pegfilgrastim's extended half-life led to prolonged stimulation of myeloblasts.
• This sustained stimulation resulted in massive, fatal leukemia cell proliferation.
• The patient's outcome was directly attributable to the pharmacokinetics of pegfilgrastim.

Implications:

• Pegfilgrastim may cause detrimental effects in AML patients, contrary to its intended use.
• Alternative G-CSFs with shorter half-lives, such as filgrastim or lenograstim, are recommended.
• Using shorter-acting G-CSFs could reduce infection risk and improve outcomes in AML patients receiving myelosuppressive chemotherapy.